Search

Your search keyword '"Katoh, Norito"' showing total 1,281 results
Start Over Author "Katoh, Norito"
1,281 results on '"Katoh, Norito"'

5. Biomarkers and patient-related factors associated with clinical outcomes in dupilumab-treated atopic dermatitis

Author

Kido-Nakahara, Makiko, Onozuka, Daisuke, Izuhara, Kenji, Saeki, Hidehisa, Nunomura, Satoshi, Takenaka, Motoi, Matsumoto, Mai, Kataoka, Yoko, Fujimoto, Rai, Kaneko, Sakae, Morita, Eishin, Tanaka, Akio, Hide, Michihiro, Okano, Tatsuro, Miyagaki, Tomomitsu, Aoki, Natsuko, Nakajima, Kimiko, Ichiyama, Susumu, Tonomura, Kyoko, Nakagawa, Yukinobu, Tamagawa-Mineoka, Risa, Masuda, Koji, Takeichi, Takuya, Akiyama, Masashi, Ishiuji, Yozo, Katsuta, Michie, Kinoshita, Yuki, Tateishi, Chiharu, Yamamoto, Aya, Morita, Akimichi, Matsuda-Hirose, Haruna, Hatano, Yutaka, Kawasaki, Hiroshi, Tanese, Keiji, Ohtsuki, Mamitaro, Kamiya, Koji, Kabata, Yudai, Abe, Riichiro, Mitsui, Hiroshi, Kawamura, Tatsuyoshi, Tsuji, Gaku, Furue, Masutaka, Katoh, Norito, and Nakahara, Takeshi

Published
2024
Full Text
View/download PDF

11. Enhanced early skin treatment for atopic dermatitis in infants reduces food allergy

Author

Morita, Kumiko, Inoue, Eisuke, Fukuie, Tatsuki, Kabashima, Shigenori, Inuzuka, Yusuke, Nishimura, Koji, Toyokuni, Kenji, Ogita, Hiroya, Kiguchi, Tomoyuki, Yoshida, Kazue, Saito, Jumpei, Hosoi, Hajime, Katoh, Norito, Morimoto, Mariko, Masuda, Koji, Kameda, Makoto, Shigekawa, Amane, Yamasaki, Koji, Nagai, Megumi, Ebisawa, Motohiro, Asaumi, Tomoyuki, Itonaga, Takaaki, Hasegawa, Shunji, Yasudo, Hiroki, Nagao, Mizuho, Fujisawa, Takao, Yasuoka, Ryuhei, Fujiyama, Toshiharu, Shimojo, Naoki, Nakano, Taiji, Kondo, Yasuto, Mori, Yuji, Kawaguchi, Takahiro, Futamura, Masaki, Sugiura, Kazumitsu, Nagai, Akiyo, Kaburagi, Sachiko, Kitazawa, Hiroshi, Kido, Hiroshi, Nakayama, Shoji F., Yamamoto-Hanada, Kiwako, Kobayashi, Tohru, Mikami, Masashi, Williams, Hywel C., Saito, Hirohisa, Saito-Abe, Mayako, Sato, Miori, Irahara, Makoto, Miyaji, Yumiko, Ishikawa, Fumi, Tsuchiya, Kunihiko, Tamagawa-Mineoka, Risa, Takaoka, Yuri, Takemura, Yutaka, Sato, Sakura, Wakiguchi, Hiroyuki, Hoshi, Miyuki, Natsume, Osamu, Yamaide, Fumiya, Seike, Miwako, and Ohya, Yukihiro

Published
2023
Full Text
View/download PDF

12. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021

Author

Saeki, Hidehisa, Ohya, Yukihiro, Furuta, Junichi, Arakawa, Hirokazu, Ichiyama, Susumu, Katsunuma, Toshio, Katoh, Norito, Tanaka, Akio, Tsunemi, Yuichiro, Nakahara, Takeshi, Nagao, Mizuho, Narita, Masami, Hide, Michihiro, Fujisawa, Takao, Futamura, Masaki, Masuda, Koji, Matsubara, Tomoyo, Murota, Hiroyuki, and Yamamoto-Hanada, Kiwako

Published
2022
Full Text
View/download PDF

17. Combining treat‐to‐target principles and shared decision‐making: International expert consensus‐based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis.

Author

Silverberg, Jonathan I., Gooderham, Melinda, Katoh, Norito, Aoki, Valeria, Pink, Andrew E., Binamer, Yousef, Rademaker, Marius, Fomina, Daria, Gutermuth, Jan, Ahn, Jiyoung, Valenzuela, Fernando, Ameen, Mahreen, Steinhoff, Martin, Kirchhof, Mark G., Lio, Peter, and Wollenberg, Andreas

Subjects
PATIENTS' attitudes, ATOPIC dermatitis, DERMATOLOGISTS, VOTING, QUALITATIVE research
Abstract

Background: Current treat‐to‐target recommendations for atopic dermatitis (AD) may not include high enough treatment targets and do not fully consider patient needs. Objective: To develop recommendations for optimized AD management, including disease severity assessments, treatment goals and targets, and guidance for treatment escalation/modification. Methods: An international group of expert dermatologists drafted a series of recommendations for AD management using insights from a global patient study and 87 expert dermatologists from 44 countries. Experts voted on recommendations using a modified eDelphi voting process. Results: The Aiming High in Eczema/Atopic Dermatitis (AHEAD) recommendations establish a novel approach to AD management, incorporating shared decision‐making and a concept for minimal disease activity (MDA). Consensus (≥70% agreement) was reached for all recommendations in 1 round of voting; strong consensus (≥90% agreement) was reached for 30/34 recommendations. In the AHEAD approach, patients select their most troublesome AD feature(s); the clinician chooses a corresponding patient‐reported severity measure and objective severity measure. Treatment targets are chosen from a list of 'moderate' and 'optimal' targets, with achievement of 'optimal' targets defined as MDA. Conclusions: Patient and expert insights led to the development of AHEAD recommendations, which establish a novel approach to AD management. Patients were not involved in the eDelphi voting process used to generate consensus on each recommendation. However, patient perspectives were captured in a global, qualitative patient research study that was considered by the experts in their initial drafting of the recommendations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Safety of Tralokinumab for the Treatment of Atopic Dermatitis in Patients with Up to 4.5 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials

Author

Reich, Kristian, primary, Langley, Richard G., additional, Silvestre, Juan Francisco, additional, Staumont-Salle, Delphine, additional, Costanzo, Antonio, additional, Pink, Andrew, additional, Paller, Amy, additional, Katoh, Norito, additional, Wollenberg, Andreas, additional, Warren, Richard B., additional, Øland, Christian Bjerregård, additional, Tindberg, Ann-Marie, additional, Gjerum, Le, additional, and Simpson, Eric, additional

Published
2024
Full Text
View/download PDF

20. Continuous Tralokinumab Treatment over 4 Years in Adults with Moderate-to-Severe Atopic Dermatitis Provides Long-Term Disease Control

Author

Blauvelt, Andrew, primary, Langley, Richard G., additional, Peris, Ketty, additional, Silvestre, Juan Francisco, additional, Katoh, Norito, additional, Tauber, Marie, additional, Pinter, Andreas, additional, Ameen, Mahreen, additional, Gooderham, Melinda, additional, Øland, Christian Bjerregård, additional, Tindberg, Ann-Marie, additional, Gjerum, Le, additional, and Reich, Kristian, additional

Published
2024
Full Text
View/download PDF

22. Measuring Signs of Atopic Dermatitis in Clinical Practice: A HOME-CP Consensus Statement

Author

MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, Jacobson, Michael E., Leshem, Yael A., Apfelbacher, Christian, Spuls, Phyllis I., Gerbens, Louise, Thomas, Kim S., Williams, Hywel C., Katoh, Norito, Howells, Laura, Schmitt, Jochen, Deckert, Stefanie, Seshadri, Rishi, Simpson, Eric, The Harmonising Outcome Measures for Eczema (HOME) initiative, Van Der Rijst, Lisa, De Graaf, Marlies, Achten, Roselie, De Bruin-Weller, Marjolein, MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, Jacobson, Michael E., Leshem, Yael A., Apfelbacher, Christian, Spuls, Phyllis I., Gerbens, Louise, Thomas, Kim S., Williams, Hywel C., Katoh, Norito, Howells, Laura, Schmitt, Jochen, Deckert, Stefanie, Seshadri, Rishi, Simpson, Eric, The Harmonising Outcome Measures for Eczema (HOME) initiative, Van Der Rijst, Lisa, De Graaf, Marlies, Achten, Roselie, and De Bruin-Weller, Marjolein

Published
2024

25. Japanese guidelines for atopic dermatitis 2020

Author

Katoh, Norito, Ohya, Yukihiro, Ikeda, Masanori, Ebihara, Tamotsu, Katayama, Ichiro, Saeki, Hidehisa, Shimojo, Naoki, Tanaka, Akio, Nakahara, Takeshi, Nagao, Mizuho, Hide, Michihiro, Fujita, Yuji, Fujisawa, Takao, Futamura, Masaki, Masuda, Koji, Murota, Hiroyuki, and Yamamoto-Hanada, Kiwako

Published
2020
Full Text
View/download PDF

31. 555 - Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials

Author

Reich, Kristian, primary, Langley, Richard G, additional, Silvestre, Juan Francisco, additional, Staumont-Salle, Delphine, additional, Costanzo, Antonio, additional, Pink, Andrew, additional, Paller, Amy, additional, Katoh, Norito, additional, Wollenberg, Andreas, additional, Warren, Richard B, additional, Øland, Christian Bjerregård, additional, Tindberg, Ann-Marie, additional, Gjerum, Le, additional, and Simpson, Eric, additional

Published
2024
Full Text
View/download PDF

32. 551 - Continuous tralokinumab treatment over 4 years in adults with moderate-to-severe atopic dermatitis provides long-term disease control

Author

Blauvelt, Andrew, primary, Langley, Richard G, additional, Peris, Ketty, additional, Silvestre, Juan Francisco, additional, Katoh, Norito, additional, Tauber, Marie, additional, Pinter, Andreas, additional, Ameen, Mahreen, additional, Gooderham, Melinda, additional, Øland, Christian Bjerregård, additional, Tindberg, Ann-Marie, additional, Gjerum, Le, additional, and Reich, Kristian, additional

Published
2024
Full Text
View/download PDF

36. Exploring patient background and biomarkers associated with the development of dupilumab-associated conjunctivitis and blepharitis

Author

Kido-Nakahara, Makiko, primary, Onozuka, Daisuke, additional, Izuhara, Kenji, additional, Saeki, Hidehisa, additional, Nunomura, Satoshi, additional, Takenaka, Motoi, additional, Matsumoto, Mai, additional, Kataoka, Yoko, additional, Fujimoto, Rai, additional, Kaneko, Sakae, additional, Morita, Eishin, additional, Tanaka, Akio, additional, Saito, Ryo, additional, Okano, Tatsuro, additional, Miyagaki, Tomomitsu, additional, Aoki, Natsuko, additional, Nakajima, Kimiko, additional, Ichiyama, Susumu, additional, Tonomura, Kyoko, additional, Nakagawa, Yukinobu, additional, Tamagawa-Mineoka, Risa, additional, Masuda, Koji, additional, Takeichi, Takuya, additional, Akiyama, Masashi, additional, Ishiuji, Yozo, additional, Katsuta, Michie, additional, Kinoshita, Yuki, additional, Tateishi, Chiharu, additional, Yamamoto, Aya, additional, Morita, Akimichi, additional, Matsuda-Hirose, Haruna, additional, Hatano, Yutaka, additional, Kawasaki, Hiroshi, additional, Fukushima-Nomura, Ayano, additional, Ohtsuki, Mamitaro, additional, Kamiya, Koji, additional, Kabata, Yudai, additional, Abe, Riichiro, additional, Mitsui, Hiroshi, additional, Kawamura, Tatsuyoshi, additional, Tsuji, Gaku, additional, Furue, Masutaka, additional, Katoh, Norito, additional, and Nakahara, Takeshi, additional

Published
2023
Full Text
View/download PDF

37. Transient improvement of urticaria induces poor adherence as assessed by Morisky Medication Adherence Scale‐8

Author

Kaneko, Sakae, Masuda, Koji, Hiragun, Takaaki, Inomata, Naoko, Furue, Masutaka, Onozuka, Daisuke, Takeuchi, Satoshi, Murota, Hiroyuki, Sugaya, Makoto, Saeki, Hidehisa, Shintani, Yoichi, Tsunemi, Yuichiro, Abe, Shinya, Kobayashi, Miwa, Kitami, Yuki, Tanioka, Miki, Imafuku, Shinichi, Abe, Masatoshi, Hagihara, Akihito, Morisky, Donald E, and Katoh, Norito

Subjects
Pharmacology and Pharmaceutical Sciences, Biomedical and Clinical Sciences, Clinical Research, 5.1 Pharmaceuticals, Management of diseases and conditions, Evaluation of treatments and therapeutic interventions, Development of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 7.1 Individual care needs, Administration, Oral, Administration, Topical, Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Japan, Male, Medication Adherence, Middle Aged, Surveys and Questionnaires, Urticaria, Young Adult, adherence, oral, topical, transient improvement, urticaria, Clinical Sciences, Dermatology & Venereal Diseases, Clinical sciences
Abstract

Poor adherence to medication is a major public health challenge. Here, we aimed to determine the adherence to oral and topical medications and to analyze underlying associated factors using the translated Japanese version of Morisky Medication Adherence Scale-8 regarding urticaria treatment. Web-based questionnaires were performed for 3096 registered dermatological patients, along with a subanalysis of 751 registered urticaria patients in this study. The adherence to oral medication was significantly associated with the frequency of hospital visits. Variables that affected the adherence to topical medication included age and experience of drug effectiveness. The rate of responses that "It felt like the symptoms had improved" varied significantly among the dermatological diseases treated with oral medications. Dermatologists should be aware that adherence to the treatment of urticaria is quite low. Regular visits and active education for patients with urticaria are mandatory in order to achieve a good therapeutic outcome by increasing the adherence.

Published
2015

38. Poor adherence to medication as assessed by the Morisky Medication Adherence Scale‐8 and low satisfaction with treatment in 237 psoriasis patients

Author

Saeki, Hidehisa, Imafuku, Shinichi, Abe, Masatoshi, Shintani, Yoichi, Onozuka, Daisuke, Hagihara, Akihito, Katoh, Norito, Murota, Hiroyuki, Takeuchi, Satoshi, Sugaya, Makoto, Tanioka, Miki, Kaneko, Sakae, Masuda, Koji, Hiragun, Takaaki, Inomata, Naoko, Kitami, Yuki, Tsunemi, Yuichiro, Abe, Shinya, Kobayashi, Miwa, Morisky, Donald E, and Furue, Masutaka

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Psoriasis, Clinical Research, 7.1 Individual care needs, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Management of diseases and conditions, Skin, Administration, Topical, Adult, Aged, Aged, 80 and over, Dermatologic Agents, Female, Humans, Japan, Male, Medication Adherence, Middle Aged, Patient Satisfaction, Skin Diseases, Surveys and Questionnaires, Young Adult, adherence, Morisky Medication Adherence Scale-8, psoriasis, sociomedical factor, treatment satisfaction, Dermatology & Venereal Diseases, Clinical sciences
Abstract

Previously we assessed the medication adherence for oral and topical remedies by a translated Japanese version of the Morisky Medication Adherence Scale-8 (MMAS-8) together with socioeconomic backgrounds in 3096 Japanese dermatological patients, and found the medication adherence, especially to topical drugs, was poor in these patients. In order to elucidate the disease-specific sociomedical factors, we further sub-analyzed the medication adherence in 237 psoriasis patients and compared it with that in other dermatological diseases such as atopic dermatitis, urticaria or tinea. This study was conducted among patients registered in monitoring system and 3096 eligible patients were enrolled. Our web-based questionnaire included the following items such as age, sex, annual income, main health-care institution, experience of effectiveness by oral or topical medication, overall satisfaction with treatment, and MMAS-8 for oral or topical medication. Mean adherence score by MMAS-8 was 5.2 for oral and 4.3 for topical medication. More patients with psoriasis used a university hospital and fewer used a private clinic compared with those with the other skin disease patients. Experience of drug effectiveness by oral medication and overall satisfaction with treatment was lower in psoriasis patients than in other patients. In oral medication, significantly better adherence was observed in those of higher age and with higher annual income. The adherence to medication, especially to topical drugs, was poor in 237 psoriasis patients. We speculated that some severe psoriasis patients were not sufficiently treated systemically and were resistant to topical therapy, leading to poor adherence.

Published
2015

40. Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system

Author

Fujisawa, Yasuhiro, Yoshikawa, Shusuke, Minagawa, Akane, Takenouchi, Tatsuya, Yokota, Kenji, Uchi, Hiroshi, Noma, Naoki, Nakamura, Yasuhiro, Asai, Jun, Kato, Junji, Fujiwara, Susumu, Fukushima, Satoshi, Uehara, Jiro, Hoashi, Toshihiko, Kaji, Tatsuya, Fujimura, Taku, Namikawa, Kenjiro, Yoshioka, Manabu, Murata, Naoki, Ogata, Dai, Matsuyama, Kanako, Hatta, Naohito, Shibayama, Yoshitsugu, Fujiyama, Toshiharu, Ishikawa, Masashi, Yamada, Daisuke, Kishi, Akiko, Nakamura, Yoshiyuki, Shimiauchi, Takatoshi, Fujii, Kazuyasu, Fujimoto, Manabu, Ihn, Hironobu, and Katoh, Norito

Published
2019
Full Text
View/download PDF

43. How to use the Harmonising Outcome Measures for Eczema Core Outcome Set for atopic dermatitis trials: a users' guide.

Author

Thomas, Kim S, Howells, Laura, Leshem, Yael A, Simpson, Eric L, Apfelbacher, Christian, Spuls, Phyllis I, Gerbens, Louise A A, Jacobson, Michael E, Katoh, Norito, Williams, Hywel C, and Stuart, Beth L

Subjects
ATOPIC dermatitis, ECZEMA, MEDICAL research personnel, SAMPLE size (Statistics), CLINICAL trials
Abstract

Background The Harmonising Outcome Measures for Eczema (HOME) initiative has agreed upon the Core Outcome Set (COS) for use in atopic dermatitis (AD) clinical trials, but additional guidance is needed to maximize its uptake. Objectives To provide answers to some of the commonly asked questions about using the HOME COS; to provide data to help with the interpretation of trial results; and to support sample size calculations for future trials. Methods and results We provide practical guidance on the use of the HOME COS for investigators planning clinical trials in patients with AD. It answers some of the common questions about using the HOME COS, how to access the outcome measurement instruments, what training/resources are needed to use them appropriately and clarifies when the COS is applicable. We also provide exemplar data to inform sample size calculations for eczema trials and encourage standardized data collection and reporting of the COS. Conclusions By encouraging adoption of the COS and facilitating consistent reporting of outcome data, it is hoped that the results of eczema trials will be more comprehensive and readily combined in meta-analyses and that patient care will subsequently be improved. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summary

Author

Reich, Kristian, primary, Thyssen, Jacob P., additional, Blauvelt, Andrew, additional, Eyerich, Kilian, additional, Soong, Weily, additional, Rice, Zakiya P., additional, Hong, H. Chih-ho, additional, Katoh, Norito, additional, Valenzuela, Fernando, additional, DiBonaventura, Marco, additional, Bratt, Tamara A., additional, Zhang, Fan, additional, Clibborn, Claire, additional, Rojo, Ricardo, additional, Valdez, Hernan, additional, and Kerkmann, Urs, additional

Published
2023
Full Text
View/download PDF

46. The ability of biomarkers to assess the severity of atopic dermatitis

Author

Nakahara, Takeshi, primary, Onozuka, Daisuke, additional, Nunomura, Satoshi, additional, Saeki, Hidehisa, additional, Takenaka, Motoi, additional, Matsumoto, Mai, additional, Kataoka, Yoko, additional, Fujimoto, Rai, additional, Kaneko, Sakae, additional, Morita, Eishin, additional, Tanaka, Akio, additional, Saito, Ryo, additional, Okano, Tatsuro, additional, Miyagaki, Tomomitsu, additional, Aoki, Natsuko, additional, Nakajima, Kimiko, additional, Ichiyama, Susumu, additional, Kido-Nakahara, Makiko, additional, Tonomura, Kyoko, additional, Nakagawa, Yukinobu, additional, Tamagawa-Mineoka, Risa, additional, Masuda, Koji, additional, Takeichi, Takuya, additional, Akiyama, Masashi, additional, Ishiuji, Yozo, additional, Katsuta, Michie, additional, Kinoshita, Yuki, additional, Tateishi, Chiharu, additional, Yamamoto, Aya, additional, Morita, Akimichi, additional, Matsuda-Hirose, Haruna, additional, Hatano, Yutaka, additional, Kawasaki, Hiroshi, additional, Fukushima-Nomura, Ayano, additional, Ohtsuki, Mamitaro, additional, Kamiya, Koji, additional, Kabata, Yudai, additional, Abe, Riichiro, additional, Mitsui, Hiroshi, additional, Kawamura, Tatsuyoshi, additional, Tsuji, Gaku, additional, Katoh, Norito, additional, Furue, Masutaka, additional, and Izuhara, Kenji, additional

Published
2023
Full Text
View/download PDF

47. A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative

Author

Zuberbier, Torsten, primary, Abdul Latiff, Amir, additional, Aggelidis, Xenofon, additional, Augustin, Matthias, additional, Balan, Radu‐Gheorghe, additional, Bangert, Christine, additional, Beck, Lisa, additional, Bieber, Thomas, additional, Bernstein, Jonathan A., additional, Bertolin Colilla, Marta, additional, Berardi, Alejandro, additional, Bedbrook, Anna, additional, Bindslev‐Jensen, Carsten, additional, Bousquet, Jean, additional, de Bruin‐Weller, Marjolein, additional, Bruscky, Dayanne, additional, Buyuktiryaki, Betul, additional, Canonica, Giorgio Walter, additional, Castro, Carla, additional, Chanturidze, Natia, additional, Chong‐Neto, Herberto Jose, additional, Chu, Chia‐Yu, additional, Chularojanamontri, Leena, additional, Cork, Michael, additional, Criado, Roberta F. J., additional, Barredo, Laia Curto, additional, Custovic, Adnan, additional, Darsow, Ulf, additional, Emurlai, Arben, additional, de Pablo, Ana, additional, Del Giacco, Stefano, additional, Girolomoni, Giampiero, additional, Deleva Jovanova, Tanja, additional, Deleuran, Mette, additional, Douladiris, Nikolaos, additional, Duarte, Bruno, additional, Dubakiene, Ruta, additional, Eller, Esben, additional, Engel‐Yeger, Batya, additional, Ensina, Luis Felipe, additional, Filho, Nelson Rosario, additional, Flohr, Carsten, additional, Fomina, Daria, additional, Francuzik, Wojciech, additional, Galimberti, Maria Laura, additional, Giménez‐Arnau, Ana M., additional, Godse, Kiran, additional, Mortz, Charlotte Gotthard, additional, Gotua, Maia, additional, Hide, Michihiro, additional, Hoetzenecker, Wolfram, additional, Hunzelmann, Nicolas, additional, Irvine, Alan, additional, Jack, Carolyn, additional, Kanavarou, Ioanna, additional, Katoh, Norito, additional, Kinaciyan, Tamar, additional, Kocatürk, Emek, additional, Kulthanan, Kanokvalai, additional, Lapeere, Hilde, additional, Lau, Susanne, additional, Machado Forti Nastri, Mariana, additional, Makris, Michael, additional, Mansour, Eli, additional, Marsland, Alexander, additional, Morelo Rocha Felix, Mara, additional, Moschione Castro, Ana Paula, additional, Nettis, Eustachio, additional, Nicolas, J. F., additional, Nosbaum, Audrey, additional, Odemyr, Mikaela, additional, Papapostolou, Niki, additional, Parisi, Claudio A. S., additional, Paudel, Sushil, additional, Peter, Jonny, additional, Pokharel, Prakash, additional, Puig, Luis, additional, Quint, Tamara, additional, Ramon, German Dario, additional, Regateiro, Frederico, additional, Ricci, Giampaolo, additional, Rosario, Cristine, additional, Sackesen, Cansin, additional, Schmid‐Grendelmeier, Peter, additional, Serra‐Baldrich, Esther, additional, Siemens, Kristina, additional, Smith, Cathrine, additional, Staubach, Petra, additional, Stevanovic, Katarina, additional, Su‐Kücük, Özlem, additional, Sussman, Gordon, additional, Tavecchio, Simona, additional, Teovska Mitrevska, Natasa, additional, Thaci, Diamant, additional, Toubi, Elias, additional, Traidl‐Hoffmann, Claudia, additional, Treudler, Regina, additional, Vadasz, Zahava, additional, van Hofman, Ingrid, additional, Ventura, Maria Teresa, additional, Wang, Zhao, additional, Werfel, Thomas, additional, Wollenberg, Andreas, additional, Yang, Ariana, additional, Weng Yew, Yik, additional, Zhao, Zuotao, additional, Zwiener, Ricardo, additional, and Worm, Margitta, additional

Published
2023
Full Text
View/download PDF

49. 649 - Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials.

Author

Reich, Kristian, Langley, Richard G, Silvestre, Juan Francisco, Staumont-Salle, Delphine, Costanzo, Antonio, Pink, Andrew, Paller, Amy, Katoh, Norito, Wollenberg, Andreas, Warren, Richard B, Øland, Christian Bjerregård, Tindberg, Ann-Marie, Gjerum, Le, and Simpson, Eric

Subjects
RESPIRATORY infections, ATOPIC dermatitis, CLINICAL trials, TERMINATION of treatment, SKIN infections
Abstract

Introduction/Background Clinical trials of up to 52 weeks showed that tralokinumab, a monoclonal antibody that specifically neutralizes interleukin-13, was efficacious and well-tolerated as monotherapy and combination with TCS. Objectives Here, we evaluate the long-term safety of tralokinumab in an integrated analysis of seven phase 3 parent trials (PTs) (NCT03131648, NCT03160885, NCT03363854, NCT03562377, NCT03526861, NCT03761537, NCT04587453), and the ongoing, up to 5-year extension study (ECZTEND; NCT03587805). Methods Two datasets were analyzed: placebo-controlled (initial 16-week period of the PTs), and all-tralokinumab combining PTs with ECZTEND including patients from first dose until end of tralokinumab exposure or data cut-off (April 30th, 2022). In the all-tralokinumab dataset, periods on placebo were disregarded. Treatment-emergent adverse events (AEs) were recorded. AEs of special interest (AESIs) were predefined. Proportions of patients with events and incidence rates (IR) per 100 patient-years of exposure (PYE) were calculated. PYE was defined as time until first event or exposure end, whichever came first, and incidence was defined as first event. Results 2693 patients (≥12 years) received tralokinumab for up to 238.5 weeks (≈4.5 years) with a median exposure time of 76.5 weeks in the all-tralokinumab dataset. Median age at baseline was 33.0 years (min-max; 12-92). 10.4% of patients were 12-17 years. 2307 patients experienced an AE (IR=202.0), most (97.3%) of which were mild-to-moderate. Serious AEs (SAEs) were reported in 226 patients (IR=4.5); SAEs were considered possibly or probably related by the investigator in 50 patients (IR=0.9). No preferred term level SAEs were reported with an IR≥0.1. Discontinuation of treatment due to AEs was low (IR=2.8). AEs leading to drug withdrawal with an IR>0.1 were dermatitis atopic (IR=0.5) and injection site reaction (ISR) (IR=0.2). Frequently reported AEs in the all-tralokinumab dataset were consistent with the placebo-controlled dataset, including nasopharyngitis (IR=18.4), upper respiratory tract infection (IR=6.9), conjunctivitis (IR=5.0), ISR (IR=3.6), conjunctivitis allergic (IR=2.7), and injection site pain (IR=1.5). AESIs, including eye disorders, skin infections requiring systemic treatment, eczema herpeticum, and malignancies, were observed in the all-tralokinumab dataset at rates similar to or lower than the placebo-controlled dataset. Conclusion Long-term use of tralokinumab, for up to 4.5 years, was well-tolerated, and the pattern of AEs was consistent with the initial placebo-controlled treatment period with no new safety signals identified. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Exploring patient background and biomarkers associated with the development of dupilumab-associated conjunctivitis and blepharitis

Author

Kido-Nakahara, Makiko, Onozuka, Daisuke, Izuhara, Kenji, Saeki, Hidehisa, Nunomura, Satoshi, Takenaka, Motoi, Matsumoto, Mai, Kataoka, Yoko, Fujimoto, Rai, Kaneko, Sakae, Morita, Eishin, Tanaka, Akio, Saito, Ryo, Okano, Tatsuro, Miyagaki, Tomomitsu, Aoki, Natsuko, Nakajima, Kimiko, Ichiyama, Susumu, Tonomura, Kyoko, Nakagawa, Yukinobu, Tamagawa-Mineoka, Risa, Masuda, Koji, Takeichi, Takuya, Akiyama, Masashi, Ishiuji, Yozo, Katsuta, Michie, Kinoshita, Yuki, Tateishi, Chiharu, Yamamoto, Aya, Morita, Akimichi, Matsuda-Hirose, Haruna, Hatano, Yutaka, Kawasaki, Hiroshi, Fukushima-Nomura, Ayano, Ohtsuki, Mamitaro, Kamiya, Koji, Kabata, Yudai, Abe, Riichiro, Mitsui, Hiroshi, Kawamura, Tatsuyoshi, Tsuji, Gaku, Furue, Masutaka, Katoh, Norito, and Nakahara, Takeshi

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results